1
|
Sellars E, Savguira M, Wu J, Cancelliere S, Jen M, Krishnan R, Hakem A, Barsyte-Lovejoy D, Hakem R, Narod SA, Kotsopoulos J, Salmena L. A high-throughput approach to identify BRCA1-downregulating compounds to enhance PARP inhibitor sensitivity. iScience 2024; 27:110180. [PMID: 38993666 PMCID: PMC11238136 DOI: 10.1016/j.isci.2024.110180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2023] [Revised: 04/29/2024] [Accepted: 06/01/2024] [Indexed: 07/13/2024] Open
Abstract
PARP inhibitors (PARPi) are efficacious in BRCA1-null tumors; however, their utility is limited in tumors with functional BRCA1. We hypothesized that pharmacologically reducing BRCA1 protein levels could enhance PARPi effectiveness in BRCA1 wild-type tumors. To identify BRCA1 downregulating agents, we generated reporter cell lines using CRISPR-mediated editing to tag endogenous BRCA1 protein with HiBiT. These reporter lines enable the sensitive measurement of BRCA1 protein levels by luminescence. Validated reporter cells were used in a pilot screen of epigenetic-modifying probes and a larger screen of more than 6,000 compounds. We identified 7 compounds that could downregulate BRCA1-HiBiT expression and synergize with olaparib. Three compounds, N-acetyl-N-acetoxy chlorobenzenesulfonamide (NANAC), A-443654, and CHIR-124, were validated to reduce BRCA1 protein levels and sensitize breast cancer cells to the toxic effects of olaparib. These results suggest that BRCA1-HiBiT reporter cells hold promise in developing agents to improve the clinical utility of PARPi.
Collapse
Affiliation(s)
- Erin Sellars
- Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada
- Women's College Research Institute, Women's College Hospital, Toronto, ON M5S 1B2, Canada
| | - Margarita Savguira
- Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada
| | - Jie Wu
- Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada
| | - Sabrina Cancelliere
- Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada
| | - Mark Jen
- Lunenfeld-Tanenbaum Research Institute, Network Biology Collaborative Centre, High-Throughput Screening, Mt. Sinai Hospital, Sinai Health System, Toronto, ON M5G 1X5, Canada
| | - Rehna Krishnan
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada
| | - Anne Hakem
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada
| | - Dalia Barsyte-Lovejoy
- Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada
- Structural Genomics Consortium, University of Toronto, Toronto, ON M5G 1L7, Canada
| | - Razqallah Hakem
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada
- Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada
| | - Steven A Narod
- Women's College Research Institute, Women's College Hospital, Toronto, ON M5S 1B2, Canada
- Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada
| | - Joanne Kotsopoulos
- Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada
- Women's College Research Institute, Women's College Hospital, Toronto, ON M5S 1B2, Canada
- Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada
| | - Leonardo Salmena
- Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada
- Women's College Research Institute, Women's College Hospital, Toronto, ON M5S 1B2, Canada
| |
Collapse
|
2
|
Vechalapu SK, Kumar R, Chatterjee N, Gupta S, Khanna S, Thimmappa PY, Senthil S, Eerlapally R, Joshi MB, Misra SK, Draksharapu A, Allimuthu D. Redox modulator iron complexes trigger intrinsic apoptosis pathway in cancer cells. iScience 2024; 27:109899. [PMID: 38799569 PMCID: PMC11126827 DOI: 10.1016/j.isci.2024.109899] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2024] [Revised: 03/21/2024] [Accepted: 05/01/2024] [Indexed: 05/29/2024] Open
Abstract
The emergence of multidrug resistance in cancer cells necessitates the development of new therapeutic modalities. One way cancer cells orchestrate energy metabolism and redox homeostasis is through overloaded iron pools directed by iron regulatory proteins, including transferrin. Here, we demonstrate that targeting redox homeostasis using nitrogen-based heterocyclic iron chelators and their iron complexes efficiently prevents the proliferation of liver cancer cells (EC50: 340 nM for IITK4003) and liver cancer 3D spheroids. These iron complexes generate highly reactive Fe(IV)=O species and accumulate lipid peroxides to promote oxidative stress in cells that impair mitochondrial function. Subsequent leakage of mitochondrial cytochrome c activates the caspase cascade to trigger the intrinsic apoptosis pathway in cancer cells. This strategy could be applied to leverage the inherent iron overload in cancer cells to selectively promote intrinsic cellular apoptosis for the development of unique iron-complex-based anticancer therapeutics.
Collapse
Affiliation(s)
- Sai Kumari Vechalapu
- Department of Chemistry, Indian Institute of Technology Kanpur, Uttar Pradesh 208016, India
| | - Rakesh Kumar
- Department of Chemistry, Indian Institute of Technology Kanpur, Uttar Pradesh 208016, India
| | - Niranjan Chatterjee
- Department of Biological Sciences and Bioengineering, Indian Institute of Technology Kanpur, Uttar Pradesh 208016, India
| | - Sikha Gupta
- Department of Chemistry, Indian Institute of Technology Kanpur, Uttar Pradesh 208016, India
| | - Shweta Khanna
- Department of Chemistry, Indian Institute of Technology Kanpur, Uttar Pradesh 208016, India
| | - Pooja Yedehalli Thimmappa
- Department of Ageing Research, Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal 576104, India
| | - Sathyapriya Senthil
- Department of Chemistry, Indian Institute of Technology Kanpur, Uttar Pradesh 208016, India
| | - Raju Eerlapally
- Department of Chemistry, Indian Institute of Technology Kanpur, Uttar Pradesh 208016, India
| | - Manjunath B. Joshi
- Department of Ageing Research, Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal 576104, India
| | - Santosh K. Misra
- Department of Biological Sciences and Bioengineering, Indian Institute of Technology Kanpur, Uttar Pradesh 208016, India
| | - Apparao Draksharapu
- Department of Chemistry, Indian Institute of Technology Kanpur, Uttar Pradesh 208016, India
| | - Dharmaraja Allimuthu
- Department of Chemistry, Indian Institute of Technology Kanpur, Uttar Pradesh 208016, India
| |
Collapse
|
3
|
Imberti C, Lok J, Coverdale JPC, Carter OWL, Fry ME, Postings ML, Kim J, Firth G, Blower PJ, Sadler PJ. Radiometal-Labeled Photoactivatable Pt(IV) Anticancer Complex for Theranostic Phototherapy. Inorg Chem 2023; 62:20745-20753. [PMID: 37643591 PMCID: PMC10731635 DOI: 10.1021/acs.inorgchem.3c02245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2023] [Indexed: 08/31/2023]
Abstract
A novel photoactivatable Pt(IV) diazido anticancer agent, Pt-succ-DFO, bearing a pendant deferoxamine (DFO) siderophore for radiometal chelation, has been synthesized for the study of its in vivo behavior with radionuclide imaging. Pt-succ-DFO complexation of Fe(III) and Ga(III) ions yielded new heterobimetallic complexes that maintain the photoactivation properties and photocytotoxicity of the parent Pt complex in human cancer cell lines. Radiolabeled Pt-succ-DFO-68Ga (t1/2 = 68 min, positron emitter) was readily prepared under mild conditions and was stable in the dark upon incubation with human serum. PET imaging of Pt-succ-DFO-68Ga in healthy mice revealed a promising biodistribution profile with rapid renal excretion and limited organ accumulation, implying that little off-target uptake is expected for this class of agents. Overall, this research provides the first in vivo imaging study of the whole-body distribution of a photoactivatable Pt(IV) azido anticancer complex and illustrates the potential of radionuclide imaging as a tool for the preclinical development of novel light-activated agents.
Collapse
Affiliation(s)
- Cinzia Imberti
- Department
of Chemistry, University of Warwick, Coventry CV4 7AL, U.K.
| | - Jamie Lok
- Department
of Chemistry, University of Warwick, Coventry CV4 7AL, U.K.
| | - James P. C. Coverdale
- School
of Pharmacy, Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT, U.K.
| | | | - Millie E. Fry
- School
of Pharmacy, Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT, U.K.
| | - Miles L. Postings
- Department
of Chemistry, University of Warwick, Coventry CV4 7AL, U.K.
| | - Jana Kim
- School
of Biomedical Engineering & Imaging Sciences, King’s College London, St Thomas’ Hospital, London SE1 7EH, U.K.
| | - George Firth
- School
of Biomedical Engineering & Imaging Sciences, King’s College London, St Thomas’ Hospital, London SE1 7EH, U.K.
| | - Philip J. Blower
- School
of Biomedical Engineering & Imaging Sciences, King’s College London, St Thomas’ Hospital, London SE1 7EH, U.K.
| | - Peter J. Sadler
- Department
of Chemistry, University of Warwick, Coventry CV4 7AL, U.K.
| |
Collapse
|
4
|
Yusoh NA, Tiley PR, James SD, Harun SN, Thomas JA, Saad N, Hii LW, Chia SL, Gill MR, Ahmad H. Discovery of Ruthenium(II) Metallocompound and Olaparib Synergy for Cancer Combination Therapy. J Med Chem 2023; 66:6922-6937. [PMID: 37185020 DOI: 10.1021/acs.jmedchem.3c00322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/17/2023]
Abstract
Synergistic drug combinations can extend the use of poly(ADP-ribose) polymerase inhibitors (PARPi) such as Olaparib to BRCA-proficient tumors and overcome acquired or de novo drug resistance. To identify new synergistic combinations for PARPi, we screened a "micro-library" comprising a mix of commercially available drugs and DNA-binding ruthenium(II) polypyridyl complexes (RPCs) for Olaparib synergy in BRCA-proficient triple-negative breast cancer cells. This identified three hits: the natural product Curcumin and two ruthenium(II)-rhenium(I) polypyridyl metallomacrocycles. All combinations identified were effective in BRCA-proficient breast cancer cells, including an Olaparib-resistant cell line, and spheroid models. Mechanistic studies indicated that synergy was achieved via DNA-damage enhancement and resultant apoptosis. Combinations showed low cytotoxicity toward non-malignant breast epithelial cells and low acute and developmental toxicity in zebrafish embryos. This work identifies RPC metallomacrocycles as a novel class of agents for cancer combination therapy and provides a proof of concept for the inclusion of metallocompounds within drug synergy screens.
Collapse
Affiliation(s)
- Nur Aininie Yusoh
- UPM-MAKNA Cancer Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia, UPM, 43400 Serdang, Selangor, Malaysia
| | - Paul R Tiley
- Department of Chemistry, Faculty of Science and Engineering, Swansea University, Swansea SA2 8PP, U.K
| | - Steffan D James
- Department of Chemistry, Faculty of Science and Engineering, Swansea University, Swansea SA2 8PP, U.K
| | - Siti Norain Harun
- Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, UPM, 43400 Serdang, Selangor, Malaysia
| | - Jim A Thomas
- Department of Chemistry, University of Sheffield, Sheffield S3 7HF, U.K
| | - Norazalina Saad
- UPM-MAKNA Cancer Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia, UPM, 43400 Serdang, Selangor, Malaysia
| | - Ling-Wei Hii
- Center for Cancer and Stem Cell Research, Development and Innovation (IRDI), Institute for Research, International Medical University, Kuala Lumpur 57000, Malaysia
| | - Suet Lin Chia
- UPM-MAKNA Cancer Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia, UPM, 43400 Serdang, Selangor, Malaysia
- Department of Microbiology, Faculty of Biotechnology and Biomolecular Science, Universiti Putra Malaysia, UPM, 43400 Serdang, Selangor, Malaysia
| | - Martin R Gill
- Department of Chemistry, Faculty of Science and Engineering, Swansea University, Swansea SA2 8PP, U.K
| | - Haslina Ahmad
- UPM-MAKNA Cancer Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia, UPM, 43400 Serdang, Selangor, Malaysia
- Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, UPM, 43400 Serdang, Selangor, Malaysia
| |
Collapse
|
5
|
Synergy of ruthenium metallo-intercalator, [Ru(dppz) 2(PIP)] 2+, with PARP inhibitor Olaparib in non-small cell lung cancer cells. Sci Rep 2023; 13:1456. [PMID: 36702871 PMCID: PMC9879939 DOI: 10.1038/s41598-023-28454-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2022] [Accepted: 01/18/2023] [Indexed: 01/27/2023] Open
Abstract
Poly(ADP-ribose) polymerase (PARP) are critical DNA repair enzymes that are activated as part of the DNA damage response (DDR). Although inhibitors of PARP (PARPi) have emerged as small molecule drugs and have shown promising therapeutic effects, PARPi used as single agents are clinically limited to patients with mutations in germline breast cancer susceptibility gene (BRCA). Thus, novel PARPi combination strategies may expand their usage and combat drug resistance. In recent years, ruthenium polypyridyl complexes (RPCs) have emerged as promising anti-cancer candidates due to their attractive DNA binding properties and distinct mechanisms of action. Previously, we reported the rational combination of the RPC DNA replication inhibitor [Ru(dppz)2(PIP)]2+ (dppz = dipyrido[3,2-a:2',3'-c]phenazine, PIP = 2-(phenyl)-imidazo[4,5-f][1,10]phenanthroline), "Ru-PIP", with the PARPi Olaparib in breast cancer cells. Here, we expand upon this work and examine the combination of Ru-PIP with Olaparib for synergy in lung cancer cells, including in 3D lung cancer spheroids, to further elucidate mechanisms of synergy and additionally assess toxicity in a zebrafish embryo model. Compared to single agents alone, Ru-PIP and Olaparib synergy was observed in both A549 and H1975 lung cancer cell lines with mild impact on normal lung fibroblast MRC5 cells. Employing the A549 cell line, synergy was confirmed by loss in clonogenic potential and reduced migration properties. Mechanistic studies indicated that synergy is accompanied by increased double-strand break (DSB) DNA damage and reactive oxygen species (ROS) levels which subsequently lead to cell death via apoptosis. Moreover, the identified combination was successfully able to inhibit the growth of A549 lung cancer spheroids and acute zebrafish embryos toxicity studies revealed that this combination showed reduced toxicity compared to single-agent Ru-PIP.
Collapse
|
6
|
Elgar C, Yusoh NA, Tiley PR, Kolozsvári N, Bennett LG, Gamble A, Péan EV, Davies ML, Staples CJ, Ahmad H, Gill MR. Ruthenium(II) Polypyridyl Complexes as FRET Donors: Structure- and Sequence-Selective DNA-Binding and Anticancer Properties. J Am Chem Soc 2023; 145:1236-1246. [PMID: 36607895 PMCID: PMC9853847 DOI: 10.1021/jacs.2c11111] [Citation(s) in RCA: 12] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Ruthenium(II) polypyridyl complexes (RPCs) that emit from metal-to-ligand charge transfer (MLCT) states have been developed as DNA probes and are being examined as potential anticancer agents. Here, we report that MLCT-emissive RPCs that bind DNA undergo Förster resonance energy transfer (FRET) with Cy5.5-labeled DNA, forming mega-Stokes shift FRET pairs. Based on this discovery, we developed a simple and rapid FRET binding assay to examine DNA-binding interactions of RPCs with diverse photophysical properties, including non-"light switch" complexes [Ru(dppz)2(5,5'dmb)]2+ and [Ru(PIP)2(5,5'dmb)]2+ (dppz = dipyridophenazine, 5,5'dmb = 5,5'-dimethyl-2,2'-bipyridine, PIP = 2-phenyl-imidazo[4,5-f][1,10]phenanthroline). Binding affinities toward duplex, G-quadruplex, three-way junction, and mismatch DNA were determined, and derived FRET donor-acceptor proximities provide information on potential binding sites. Molecules characterized by this method demonstrate encouraging anticancer properties, including synergy with the PARP inhibitor Olaparib, and mechanistic studies indicate that [Ru(PIP)2(5,5'dmb)]2+ acts to block DNA replication fork progression.
Collapse
Affiliation(s)
- Christopher
E. Elgar
- Department
of Chemistry, Faculty of Science and Engineering, Swansea University, Swansea SA2 8PP, U.K.
| | - Nur Aininie Yusoh
- UPM-MAKNA
Cancer Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia
| | - Paul R. Tiley
- Department
of Chemistry, Faculty of Science and Engineering, Swansea University, Swansea SA2 8PP, U.K.
| | - Natália Kolozsvári
- Department
of Chemistry, Faculty of Science and Engineering, Swansea University, Swansea SA2 8PP, U.K.
| | - Laura G. Bennett
- North
West Cancer Research Institute, School of Medical Sciences, Bangor University, Bangor LL57 2DG, U.K.
| | - Amelia Gamble
- North
West Cancer Research Institute, School of Medical Sciences, Bangor University, Bangor LL57 2DG, U.K.
| | - Emmanuel V. Péan
- SPECIFIC
IKC, Materials Science and Engineering, Faculty of Science and Engineering, Swansea University, Swansea SA1 8EN, U.K.
| | - Matthew L. Davies
- SPECIFIC
IKC, Materials Science and Engineering, Faculty of Science and Engineering, Swansea University, Swansea SA1 8EN, U.K.
| | - Christopher J. Staples
- North
West Cancer Research Institute, School of Medical Sciences, Bangor University, Bangor LL57 2DG, U.K.
| | - Haslina Ahmad
- UPM-MAKNA
Cancer Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia,Department
of Chemistry, Faculty of Science, Universiti
Putra Malaysia, 43400 Serdang, Selangor, Malaysia
| | - Martin R. Gill
- Department
of Chemistry, Faculty of Science and Engineering, Swansea University, Swansea SA2 8PP, U.K.,
| |
Collapse
|
7
|
Dömötör O, Teixeira RG, Spengler G, Avecilla F, Marques F, Lenis-Rojas OA, Matos CP, de Almeida RFM, Enyedy ÉA, Tomaz AI. Ruthenium(II) polypyridyl complexes with benzothiophene and benzimidazole derivatives: Synthesis, antitumor activity, solution studies and biospeciation. J Inorg Biochem 2023; 238:112058. [PMID: 36375357 DOI: 10.1016/j.jinorgbio.2022.112058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2022] [Revised: 10/27/2022] [Accepted: 10/28/2022] [Indexed: 11/08/2022]
Abstract
With the aim to incorporate pharmacophore motifs into the Ru(II)-polypyridyl framework, compounds [Ru(II)(1,10-phenantroline)2(2-(2-pyridyl)benzo[b]thiophene)](CF3SO3)2 (1) and [Ru(II)(1,10-phenantroline)2(2-(2-pyridyl)benzimidazole)](CF3SO3)2 (2) were prepared, characterized and tested for their antitumor potential. The solid-state structure of the compounds was confirmed by single-crystal X-ray diffraction analysis. The solution behavior of both complexes was investigated, namely their solubility, stability, and lipophilicity in physiological mimetic conditions, as well as an eventual uptake by passive diffusion. In vitro anticancer activity of the complexes on ovarian and different colon cancer cells and apoptosis induction by the complexes were studied. A slow transformation process was observed for complex 1 in aqueous solution when exposed to sunlight, while complex 2 undergoes deprotonation (pKa = 7.59). The lipophilicity of this latter complex depends strongly on the pH and ionic strength. In contrast, 1 is rather hydrophilic under various conditions. Complex 1 was highly cytotoxic on Colo-205 human colon (IC50 = 7.87 μM) and A2780 ovarian (IC50 = 2.2 μM) adenocarcinoma cell lines, while 2 displayed moderate anticancer activity (30.9 μM and 18.0 μM, respectively). The complexes induced late apoptosis and necrosis. Only a weak binding of the complexes to human serum albumin, the main transport protein in blood serum, was found. However, a more significant binding to calf thymus DNA was observed in UV-visible titrations and fluorometric dye displacement studies. Detailed analysis of fluorescence lifetime data collected for the latter systems reveals not only the partial intercalation of the complexes, but goes beyond the usual simplified interpretations.
Collapse
Affiliation(s)
- Orsolya Dömötör
- Department of Inorganic and Analytical Chemistry, Interdisciplinary Excellence Centre, University of Szeged, Dóm tér 7, H-6720 Szeged, Hungary; MTA-SZTE Lendület Functional Metal Complexes Research Group, University of Szeged, Dóm tér 7, H-6720 Szeged, Hungary.
| | - Ricardo G Teixeira
- Centro de Química Estrutural, Institute of Molecular Sciences, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, 1049-016 Lisboa, Portugal
| | - Gabriella Spengler
- MTA-SZTE Lendület Functional Metal Complexes Research Group, University of Szeged, Dóm tér 7, H-6720 Szeged, Hungary; Department of Medical Microbiology, Albert Szent-Györgyi Health Center and Albert Szent-Györgyi Medical School, University of Szeged, Semmelweis u. 6, H-6725 Szeged, Hungary
| | - Fernando Avecilla
- Universidade da Coruña, Grupo NanoToxGen, Centro de Investigacións Científicas Avanzadas (CICA), Departamento de Química, Facultade de Ciencias, Campus de A Coruña, 15071A Coruña, Spain
| | - Fernanda Marques
- Centro de Ciências e Tecnologias Nucleares and Departamento de Ciências e Engenharia Nucleares, Instituto Superior Técnico, Universidade de Lisboa, EN 10 (km 139,7), 2695-066 Bobadela, Loures, Portugal
| | - Oscar A Lenis-Rojas
- Centro de Química Estrutural, Institute of Molecular Sciences, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, 1049-016 Lisboa, Portugal
| | - Cristina P Matos
- Centro de Química Estrutural, Institute of Molecular Sciences, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, 1049-016 Lisboa, Portugal
| | - Rodrigo F M de Almeida
- Centro de Química Estrutural, Institute of Molecular Sciences, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, 1049-016 Lisboa, Portugal
| | - Éva A Enyedy
- Department of Inorganic and Analytical Chemistry, Interdisciplinary Excellence Centre, University of Szeged, Dóm tér 7, H-6720 Szeged, Hungary; MTA-SZTE Lendület Functional Metal Complexes Research Group, University of Szeged, Dóm tér 7, H-6720 Szeged, Hungary
| | - Ana Isabel Tomaz
- Centro de Química Estrutural, Institute of Molecular Sciences, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, 1049-016 Lisboa, Portugal.
| |
Collapse
|
8
|
Synthesis, characterization and in vitro cytotoxicity of ruthenium(II) metronidazole complexes: Cell cycle arrest at G1/S transition and apoptosis induction in MCF-7 cells. J Inorg Biochem 2022; 237:112022. [PMID: 36244314 DOI: 10.1016/j.jinorgbio.2022.112022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Revised: 09/25/2022] [Accepted: 10/02/2022] [Indexed: 11/05/2022]
Abstract
Ruthenium compounds are known to be potential drug candidates since they offer the potential for reduced toxicity. Furthermore, the various oxidation states, different mechanisms of action and ligand substitution kinetics give them advantages over platinum-based complexes, making them suitable for use in biological applications. So, herein, novel ruthenium(II) complexes with metronidazole as ligand were obtained [RuCl(MTNZ)(dppb)(4,4'-Mebipy)]PF6 (1), [RuCl(MTNZ)(dppb)(4,4'-Methoxybipy)]PF6 (2), [RuCl(MTNZ)(dppb)(bipy)]PF6 (3) and [RuCl(MTNZ)(dppb)(phen)]PF6 (4) where, MTNZ = metronidazole, dppb = 1,4-bis(diphenylphosphino)butane, 4,4'-Mebipy = 4,4'-dimethyl-2,2'-bipyridine, 4,4'-Methoxybipy = 4,4'-dimethoxy-2,2'-bipyridine, bipy = 2,2'-bipyridine and phen = 1,10-phenanthroline. The complexes were characterized by elemental analysis, molar conductivity, infrared and UV-Vis spectroscopy, cyclic voltammetry, 31P{1H}, 1H, 13C{1H} and Dept 135 NMR and mass spectrometry. The interaction of complexes 1-4 with DNA was evaluated, and their cytotoxicity profiles were determined on four different tumor cell lines derived from human cancers (SK-MEL-147, melanoma; HepG2, hepatocarcinoma; MCF-7, estrogen-positive breast cancer; A549, non-small cell lung cancer). We demonstrated that complexes (1) and (3) are promising antitumor agents once inhibited the proliferative behavior of MCF-7 cells and induced apoptosis.
Collapse
|
9
|
Yim J, Park SB. Label-Free Target Identification Reveals the Anticancer Mechanism of a Rhenium Isonitrile Complex. Front Chem 2022; 10:850638. [PMID: 35372261 PMCID: PMC8964423 DOI: 10.3389/fchem.2022.850638] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2022] [Accepted: 02/25/2022] [Indexed: 01/21/2023] Open
Abstract
Elucidation of the molecular mechanism of therapeutic agents and potential candidates is in high demand. Interestingly, rhenium-based complexes have shown a highly selective anticancer effect, only on cancer cells, unlike platinum-based drugs, such as cisplatin and carboplatin. These differences might be attributed to their different molecular targets. We confirmed that the target of tricarbonyl rhenium isonitrile polypyridyl (TRIP) complex is a protein, not DNA, using ICP-MS analysis and identified heat shock protein 60 (HSP60) as its target protein using a label-free target identification method. The subsequent biological evaluation revealed that TRIP directly inhibits the chaperone function of HSP60 and induces the accumulation of misfolded proteins in mitochondria, thereby leading to the activation of mitochondrial unfolded protein response (mtUPR)-mediated JNK2/AP-1/CHOP apoptotic pathway.
Collapse
Affiliation(s)
- Junhyeong Yim
- Department of Biophysics and Chemical Biology, Seoul National University, Seoul, South Korea
| | - Seung Bum Park
- Department of Biophysics and Chemical Biology, Seoul National University, Seoul, South Korea
- CRI Center for Chemical Proteomics, Department of Chemistry, Seoul National University, Seoul, South Korea
- *Correspondence: Seung Bum Park,
| |
Collapse
|
10
|
Kumar S, Singh S, Kumar A, Murthy K, Kumar Singh A. pH-Responsive luminescence sensing, photoredox catalysis and photodynamic applications of ruthenium(II) photosensitizers bearing imidazo[4,5-f][1,10]phenanthroline scaffolds. Coord Chem Rev 2022. [DOI: 10.1016/j.ccr.2021.214272] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
11
|
Ng CH, Tan TH, Tioh NH, Seng HL, Ahmad M, Ng SW, Gan WK, Low ML, Lai JW, Zulkefeli M. Synthesis, characterization and multiple targeting with selectivity: Anticancer property of ternary metal phenanthroline-maltol complexes. J Inorg Biochem 2021; 220:111453. [PMID: 33895694 DOI: 10.1016/j.jinorgbio.2021.111453] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2020] [Revised: 03/26/2021] [Accepted: 03/26/2021] [Indexed: 02/01/2023]
Abstract
The cobalt(II), copper(II) and zinc(II) complexes of 1,10-phenanthroline (phen) and maltol (mal) (complexes 1, 2, 3 respectively) were prepared from their respective metal(II) chlorides and were characterized by FT-IR, elemental analysis, UV spectroscopy, molar conductivity, p-nitrosodimethylaniline assay and mass spectrometry. The X-ray structure of a single crystal of the zinc(II) analogue reveals a square pyramidal structure with distinctly shorter apical chloride bond. All complexes were evaluated for their anticancer property on breast cancer cell lines MCF-7 and MDA-MB-231, and normal cell line MCF-10A, using (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and morphological studies. Complex 2 was most potent for 24, 48 and 72 h treatment of cancer cells but it was not selective towards cancer over normal cells. The mechanistic studies of the cobalt(II) complex 1 involved apoptosis assay, cell cycle analysis, dichloro-dihydro-fluorescein diacetate assay, intracellular reactive oxygen species assay and proteasome inhibition assay. Complex 1 induced low apoptosis, generated low level of ROS and did not inhibit proteasome in normal cells. The study of the DNA binding and nucleolytic properties of complexes 1-3 in the absence or presence of H2O2 or sodium ascorbate revealed that only complex 1 was not nucleolytic.
Collapse
Affiliation(s)
- Chew Hee Ng
- Department of Pharmaceutical Chemistry, School of Pharmacy, International Medical University, Bukit Jalil, 57000, Kuala Lumpur, Malaysia.
| | - Thean Heng Tan
- Faculty of Science and Engineering, Universiti Tunku Abdul Rahman, 53300 Kuala Lumpur, Malaysia
| | - Ngee Heng Tioh
- Faculty of Science and Engineering, Universiti Tunku Abdul Rahman, 53300 Kuala Lumpur, Malaysia
| | - Hoi Ling Seng
- Faculty of Science and Engineering, Universiti Tunku Abdul Rahman, 53300 Kuala Lumpur, Malaysia
| | - Munirah Ahmad
- Molecular Pathology Unit, Cancer Research Center, Institute for Medical Research, 50588 Kuala Lumpur, Malaysia
| | - Seik Weng Ng
- UCSI University, Cheras, 56000, Kuala Lumpur, Malaysia
| | - Wei Khang Gan
- School of Postgraduate Studies, International Medical University, Bukit Jalil, Kuala Lumpur 57000, Malaysia
| | - May Lee Low
- Department of Pharmaceutical Chemistry, School of Pharmacy, International Medical University, Bukit Jalil, 57000, Kuala Lumpur, Malaysia
| | - Jing Wei Lai
- Department of Pharmaceutical Chemistry, School of Pharmacy, International Medical University, Bukit Jalil, 57000, Kuala Lumpur, Malaysia
| | - Mohd Zulkefeli
- Department of Pharmaceutical Chemistry, School of Pharmacy, International Medical University, Bukit Jalil, 57000, Kuala Lumpur, Malaysia
| |
Collapse
|
12
|
Allison M, Caramés-Méndez P, Pask CM, Phillips RM, Lord RM, McGowan PC. Bis(bipyridine)ruthenium(II) Ferrocenyl β-Diketonate Complexes: Exhibiting Nanomolar Potency against Human Cancer Cell Lines. Chemistry 2021; 27:3737-3744. [PMID: 33073884 DOI: 10.1002/chem.202004024] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2020] [Revised: 10/09/2020] [Indexed: 12/23/2022]
Abstract
The synthesis and characterization of new bis(bipyridine)ruthenium(II) ferrocenyl β-diketonate complexes, [(bpy)2 Ru(Fc-acac)][PF6 ] (bpy=2,2'-bipyridine; Fc-acac=functionalized ferrocenyl β-diketonate ligand) are reported. Alongside clinical platinum drugs, these bimetallic ruthenium-iron complexes have been screened for their cytotoxicity against MIA PaCa-2 (human pancreatic carcinoma), HCT116 p53+/+ (human colon carcinoma, p53-wild type) and ARPE-19 (human retinal pigment epithelial) cell lines. With the exception of one complex, the library exhibit nanomolar potency against cancerous cell lines, and their relative potencies are up to 40x, 400x and 72x more cytotoxic than cisplatin, carboplatin and oxaliplatin, respectively. Under hypoxic conditions, the complexes remain cytotoxic (sub-micromolar range), highlighting their potential in targeting hypoxic tumor regions. The Comet assay was used to determine their ability to damage DNA, and results show dose dependent damage which correlates well with the cytotoxicity results. Their potential to treat bacterial and fungal strains has been determined, and highlight complexes have selective growth inhibition of up to 87-100 % against Staphylococcus aureus and Candida albicans.
Collapse
Affiliation(s)
- Matthew Allison
- School of Chemistry, University of Leeds, Woodhouse Lane, Leeds, LS2 9JT, UK
| | - Pablo Caramés-Méndez
- School of Chemistry, University of Leeds, Woodhouse Lane, Leeds, LS2 9JT, UK
- Department of Pharmacy, University of Huddersfield, Huddersfield, HD1 3DH, UK
| | - Christopher M Pask
- School of Chemistry, University of Leeds, Woodhouse Lane, Leeds, LS2 9JT, UK
| | - Roger M Phillips
- Department of Pharmacy, University of Huddersfield, Huddersfield, HD1 3DH, UK
| | - Rianne M Lord
- School of Chemistry, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK
- School of Chemistry and Biosciences, University of Bradford, Bradford, BD7 1DP, UK
| | - Patrick C McGowan
- School of Chemistry, University of Leeds, Woodhouse Lane, Leeds, LS2 9JT, UK
| |
Collapse
|
13
|
Liu ZY, Zhang J, Sun YM, Zhu CF, Lu YN, Wu JZ, Li J, Liu HY, Ye Y. Photodynamic antitumor activity of Ru(ii) complexes of imidazo-phenanthroline conjugated hydroxybenzoic acid as tumor targeting photosensitizers. J Mater Chem B 2021; 8:438-446. [PMID: 31833531 DOI: 10.1039/c9tb02103e] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Two novel Ru(ii) polypyridyl complexes bearing imidazo-phenanthroline conjugated hydroxybenzoic acid groups were designed to enhance the tumor targeting ability as photosensitizers for photodynamic therapy. [Ru(bpy)2(phcpip)] (ClO4)2 (Ru-1) and [Ru(bpy)2(ohcpip)] (ClO4)2 (Ru-2) (bpy = 2,2'-bipyridine; phcpip = 2-(3-carboxyl-4-hydroxyphenyl) imidazo [4,5-f]phenanthroline; ohcpip = 2-(2-hydroxyl-3-carboxyphenyl) imidazo [4,5-f] [1,10] phenanthroline) were synthesized and their photodynamic antitumor activities were investigated. Both complexes displayed high photocytotoxicity toward cancerous cell lines HepG2, A549, MCF-7, and MDA-MB-231, but low photocytotoxicity toward normal cell lines GES-1 and Huvec. They were mainly localized at the nucleus of HepG2 cells after 24 h incubation, arrested the cell cycle at the G2/M phase and induced cancer cell apoptosis through reactive oxygen species (ROS) mediated pathways. Tumor targeting of the complexes is attributed to stronger molecular binding to DNA.
Collapse
Affiliation(s)
- Ze-Yu Liu
- School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P. R. China.
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Synthesis and Optimization of Mesoporous Silica Nanoparticles for Ruthenium Polypyridyl Drug Delivery. Pharmaceutics 2021; 13:pharmaceutics13020150. [PMID: 33498795 PMCID: PMC7910993 DOI: 10.3390/pharmaceutics13020150] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2020] [Revised: 12/23/2020] [Accepted: 12/26/2020] [Indexed: 12/30/2022] Open
Abstract
The ruthenium polypyridyl complex [Ru(dppz)2PIP]2+ (dppz: dipyridophenazine, PIP: (2-(phenyl)-imidazo[4,5-f ][1,10]phenanthroline), or Ru-PIP, is a potential anticancer drug that acts by inhibiting DNA replication. Due to the poor dissolution of Ru-PIP in aqueous media, a drug delivery agent would be a useful approach to overcome its limited bioavailability. Mesoporous silica nanoparticles (MSNs) were synthesized via a co-condensation method by using a phenanthrolinium salt with a 16 carbon length chain (Phen-C16) as the template. Optimization of the synthesis conditions by Box–Behnken design (BBD) generated MSNs with high surface area response at 833.9 m2g−1. Ru-PIP was effectively entrapped in MSNs at 18.84%. Drug release profile analysis showed that Ru-PIP is gradually released, with a cumulative release percentage of approximately 50% at 72 h. The release kinetic profile implied that Ru-PIP was released from MSN by diffusion. The in vitro cytotoxicity of Ru-PIP, both free and MSN-encapsulated, was studied in Hela, A549, and T24 cancer cell lines. While treatment of Ru-PIP alone is moderately cytotoxic, encapsulated Ru-PIP exerted significant cytotoxicity upon all the cell lines, with half maximal inhibitory concentration (IC50) values determined by MTT (([3-(4,5-dimethylthiazol-2-yl)-2,5-dephenyltetrazolium bromide]) assay at 48 h exposure substantially decreasing from >30 µM to <10 µM as a result of MSN encapsulation. The mechanistic potential of cytotoxicity on cell cycle distribution showed an increase in G1/S phase populations in all three cell lines. The findings indicate that MSN is an ideal drug delivery agent, as it is able to sustainably release Ru-PIP by diffusion in a prolonged treatment period.
Collapse
|
15
|
Faria RS, Silva HD, Mello-Andrade F, Pires WC, de Castro Pereira F, de Lima AP, de Fátima Oliveira Santos S, Teixeira TM, da Silva PFF, Naves PLF, Batista AA, da Silva Oliveira RJ, Reis RM, de Paula Silveira-Lacerda E. Ruthenium(II)/Benzonitrile Complex Induces Cytotoxic Effect in Sarcoma-180 Cells by Caspase-Mediated and Tp53/p21-Mediated Apoptosis, with Moderate Brine Shrimp Toxicity. Biol Trace Elem Res 2020; 198:669-680. [PMID: 32266641 DOI: 10.1007/s12011-020-02098-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/01/2019] [Accepted: 02/26/2020] [Indexed: 12/12/2022]
Abstract
Ruthenium(II)/benzonitrile complexes have demonstrated promising anticancer properties. Considering that there are no specific therapies for treating sarcoma, we decided to evaluate the cytotoxic, genotoxic, and lethal effects of cis-[RuCl(BzCN)(phen)(dppb)]PF6 (BzCN = benzonitrile; phen = 1,10-phenanthroline; dppb = 1,4-bis-(diphenylphosphino)butane), as well as the mechanism of cell death induction that occurs against murine sarcoma-180 tumor. Thus, MTT assay was applied to assess the ruthenium cytotoxicity, showing that the compound is a more potent inhibitor for the sarcoma-180 tumor cell viability than normal cells (lymphocytes). The comet assay indicated low genotoxic for normal cells. cis-[RuCl(BzCN)(phen)(dppb)]PF6 also showed moderate lethality in Artemia salina. The complex induced cell cycle arrest in the G0/G1 phase in sarcoma-180 cells. In addition, the complex caused S180 cells to die by apoptosis by an increase in Annexin-V-positive cells and morphological changes typical of apoptotic cells. Additionally, cis-[RuCl(BzCN)(phen)(dppb)]PF6 increased the gene expression of Bax, Casp3, and Tp53 in S180 cells. By using a western blot, we observed an increased protein level of TNF-R2, Bax, and p21. In conclusion, cis-[RuCl(BzCN)(phen)(dppb)]PF6 is active and selective for sarcoma-180 cells, leading to cell cycle arrest at the G0/G1 and cell death through a caspases-mediated and Tp53/p21-mediated pathway.
Collapse
Affiliation(s)
- Raquel Santos Faria
- Department of Genetics, Laboratory of Molecular Genetics and Cytogenetics, Institute of Biological Sciences, Federal University of Goiás, Avenida Esperança, s/n, Campus Samambaia (Campus II), Cx. Postal 131, Goiania, GO, 74690-900, Brazil
| | - Hugo Delleon Silva
- Department of Genetics, Laboratory of Molecular Genetics and Cytogenetics, Institute of Biological Sciences, Federal University of Goiás, Avenida Esperança, s/n, Campus Samambaia (Campus II), Cx. Postal 131, Goiania, GO, 74690-900, Brazil
- Uni-Anhanguera University Center of Goias, Goiania, Goiás, 74423-115, Brazil
| | - Francyelli Mello-Andrade
- Department of Genetics, Laboratory of Molecular Genetics and Cytogenetics, Institute of Biological Sciences, Federal University of Goiás, Avenida Esperança, s/n, Campus Samambaia (Campus II), Cx. Postal 131, Goiania, GO, 74690-900, Brazil
- Department of Chemistry, Federal Institute of Education, Science and Technology of Goiás, Goiania, Goiás, 74055-110, Brazil
| | - Wanessa Carvalho Pires
- Department of Genetics, Laboratory of Molecular Genetics and Cytogenetics, Institute of Biological Sciences, Federal University of Goiás, Avenida Esperança, s/n, Campus Samambaia (Campus II), Cx. Postal 131, Goiania, GO, 74690-900, Brazil
| | - Flávia de Castro Pereira
- Department of Genetics, Laboratory of Molecular Genetics and Cytogenetics, Institute of Biological Sciences, Federal University of Goiás, Avenida Esperança, s/n, Campus Samambaia (Campus II), Cx. Postal 131, Goiania, GO, 74690-900, Brazil
| | - Aliny Pereira de Lima
- Department of Genetics, Laboratory of Molecular Genetics and Cytogenetics, Institute of Biological Sciences, Federal University of Goiás, Avenida Esperança, s/n, Campus Samambaia (Campus II), Cx. Postal 131, Goiania, GO, 74690-900, Brazil
- Faculty of Brazil Institute (FIBRA), Anapolis, Goiás, 75133-050, Brazil
| | - Sônia de Fátima Oliveira Santos
- Department of Genetics, Laboratory of Molecular Genetics and Cytogenetics, Institute of Biological Sciences, Federal University of Goiás, Avenida Esperança, s/n, Campus Samambaia (Campus II), Cx. Postal 131, Goiania, GO, 74690-900, Brazil
| | - Thallita Monteiro Teixeira
- Department of Genetics, Laboratory of Molecular Genetics and Cytogenetics, Institute of Biological Sciences, Federal University of Goiás, Avenida Esperança, s/n, Campus Samambaia (Campus II), Cx. Postal 131, Goiania, GO, 74690-900, Brazil
| | - Paula Francinete Faustino da Silva
- Department of Genetics, Laboratory of Molecular Genetics and Cytogenetics, Institute of Biological Sciences, Federal University of Goiás, Avenida Esperança, s/n, Campus Samambaia (Campus II), Cx. Postal 131, Goiania, GO, 74690-900, Brazil
| | | | - Alzir Azevedo Batista
- Department of Chemistry, Federal University of São Carlos, Sao Carlos, São Paulo, 13565-905, Brazil
| | | | - Rui Manuel Reis
- Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, 14784-400, Brazil
| | - Elisângela de Paula Silveira-Lacerda
- Department of Genetics, Laboratory of Molecular Genetics and Cytogenetics, Institute of Biological Sciences, Federal University of Goiás, Avenida Esperança, s/n, Campus Samambaia (Campus II), Cx. Postal 131, Goiania, GO, 74690-900, Brazil.
| |
Collapse
|
16
|
Yusoh NA, Ahmad H, Gill MR. Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy. ChemMedChem 2020; 15:2121-2135. [PMID: 32812709 PMCID: PMC7754470 DOI: 10.1002/cmdc.202000391] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Indexed: 12/24/2022]
Abstract
Platinum drugs are heavily used first-line chemotherapeutic agents for many solid tumours and have stimulated substantial interest in the biological activity of DNA-binding metal complexes. These complexes generate DNA lesions which trigger the activation of DNA damage response (DDR) pathways that are essential to maintain genomic integrity. Cancer cells exploit this intrinsic DNA repair network to counteract many types of chemotherapies. Now, advances in the molecular biology of cancer has paved the way for the combination of DDR inhibitors such as poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) and agents that induce high levels of DNA replication stress or single-strand break damage for synergistic cancer cell killing. In this review, we summarise early-stage, preclinical and clinical findings exploring platinum and emerging ruthenium anti-cancer complexes alongside PARPi in combination therapy for cancer and also describe emerging work on the ability of ruthenium and gold complexes to directly inhibit PARP activity.
Collapse
Affiliation(s)
- Nur Aininie Yusoh
- Department of ChemistryFaculty of ScienceUniversiti Putra Malaysia43400 UPMSerdang, SelangorMalaysia
| | - Haslina Ahmad
- Department of ChemistryFaculty of ScienceUniversiti Putra Malaysia43400 UPMSerdang, SelangorMalaysia
- Integrated Chemical BiophysicsFaculty of ScienceUniversiti Putra Malaysia43400 UPMSerdang, SelangorMalaysia
| | - Martin R. Gill
- Department of ChemistrySwansea UniversitySwanseaWales (UK
| |
Collapse
|
17
|
Gill MR, Walker MG, Able S, Tietz O, Lakshminarayanan A, Anderson R, Chalk R, El-Sagheer AH, Brown T, Thomas JA, Vallis KA. An 111In-labelled bis-ruthenium(ii) dipyridophenazine theranostic complex: mismatch DNA binding and selective radiotoxicity towards MMR-deficient cancer cells. Chem Sci 2020; 11:8936-8944. [PMID: 33815738 PMCID: PMC7989384 DOI: 10.1039/d0sc02825h] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2020] [Accepted: 08/04/2020] [Indexed: 12/23/2022] Open
Abstract
Theranostic radionuclides that emit Auger electrons (AE) can generate highly localised DNA damage and the accompanying gamma ray emission can be used for single-photon emission computed tomography (SPECT) imaging. Mismatched DNA base pairs (mismatches) are DNA lesions that are abundant in cells deficient in MMR (mismatch mediated repair) proteins. This form of genetic instability is prevalent in the MMR-deficient subset of colorectal cancers and is a potential target for AE radiotherapeutics. Herein we report the synthesis of a mismatch DNA binding bis-ruthenium(ii) dipyridophenazine (dppz) complex that can be radiolabelled with the Auger electron emitting radionuclide indium-111 (111In). Greater stabilisation accompanied by enhanced MLCT (metal to ligand charge-transfer) luminescence of both the bis-Ru(dppz) chelator and non-radioactive indium-loaded complex was observed in the presence of a TT mismatch-containing duplex compared to matched DNA. The radioactive construct [111In]In-bisRu(dppz) ([111In][In-2]4+) targets cell nuclei and is radiotoxic towards MMR-deficient human colorectal cancer cells showing substantially less detrimental effects in a paired cell line with restored MMR function. Additional cell line studies revealed that [111In][In-2]4+ is preferentially radiotoxic towards MMR-deficient colorectal cancer cells accompanied by increased DNA damage due to 111In decay. The biodistribution of [111In][In-2]4+ in live mice was demonstrated using SPECT. These results illustrate how a Ru(ii) polypyridyl complex can incorporate mismatch DNA binding and radiometal chelation in a single molecule, generating a DNA-targeting AE radiopharmaceutical that displays selective radiotoxicity towards MMR-deficient cancer cells and is compatible with whole organism SPECT imaging.
Collapse
Affiliation(s)
- Martin R Gill
- Oxford Institute for Radiation Oncology , Department of Oncology , University of Oxford , Oxford , UK .
- Department of Chemistry , Swansea University , Swansea , Wales , UK .
| | - Michael G Walker
- Department of Chemistry , University of Sheffield , Sheffield , UK
| | - Sarah Able
- Oxford Institute for Radiation Oncology , Department of Oncology , University of Oxford , Oxford , UK .
| | - Ole Tietz
- Oxford Institute for Radiation Oncology , Department of Oncology , University of Oxford , Oxford , UK .
| | - Abirami Lakshminarayanan
- Oxford Institute for Radiation Oncology , Department of Oncology , University of Oxford , Oxford , UK .
- Chemistry Research Laboratory , Department of Chemistry , University of Oxford , Oxford OX1 3TA , UK
| | - Rachel Anderson
- Oxford Institute for Radiation Oncology , Department of Oncology , University of Oxford , Oxford , UK .
| | - Rod Chalk
- Structural Genomics Consortium , University of Oxford , Oxford , UK
| | - Afaf H El-Sagheer
- Chemistry Research Laboratory , Department of Chemistry , University of Oxford , Oxford OX1 3TA , UK
- Chemistry Branch , Department of Science and Mathematics , Faculty of Petroleum and Mining Engineering , Suez University , Suez 43721 , Egypt
| | - Tom Brown
- Chemistry Research Laboratory , Department of Chemistry , University of Oxford , Oxford OX1 3TA , UK
| | - Jim A Thomas
- Department of Chemistry , University of Sheffield , Sheffield , UK
| | - Katherine A Vallis
- Oxford Institute for Radiation Oncology , Department of Oncology , University of Oxford , Oxford , UK .
| |
Collapse
|
18
|
Camp CP, Peterson IL, Knoff DS, Melcher LG, Maxwell CJ, Cohen AT, Wertheimer AM, Kim M. Non-cytotoxic Dityrosine Photocrosslinked Polymeric Materials With Targeted Elastic Moduli. Front Chem 2020; 8:173. [PMID: 32232027 PMCID: PMC7082925 DOI: 10.3389/fchem.2020.00173] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2020] [Accepted: 02/26/2020] [Indexed: 12/18/2022] Open
Abstract
Controlling mechanical properties of polymeric biomaterials, including the elastic modulus, is critical to direct cell behavior, such as proliferation and differentiation. Dityrosine photocrosslinking is an attractive and simple method to prepare materials that exhibit a wide range of elastic moduli by rapidly crosslinking tyrosyl-containing polymers. However, high concentrations of commonly used oxidative crosslinking reagents, such as ruthenium-based photoinitiators and persulfates, present cytotoxicity concerns. We found the elastic moduli of materials prepared by crosslinking an artificial protein with tightly controlled tyrosine molarity can be modulated up to 40 kPa by adjusting photoinitiator and persulfate concentrations. Formulations with various concentrations of the crosslinking reagents were able to target a similar material elastic modulus, but excess unreacted persulfate resulted in cytotoxic materials. Therefore, we identified a systematic method to prepare non-cytotoxic photocrosslinked polymeric materials with targeted elastic moduli for potential biomaterials applications in diverse fields, including tissue engineering and 3D bioprinting.
Collapse
Affiliation(s)
- Christopher P. Camp
- Department of Biomedical Engineering, University of Arizona, Tucson, AZ, United States
| | - Ingrid L. Peterson
- Applied Biosciences GIDP, University of Arizona, Tucson, AZ, United States
- BIO5 Institute, University of Arizona, Tucson, AZ, United States
| | - David S. Knoff
- Department of Biomedical Engineering, University of Arizona, Tucson, AZ, United States
| | | | - Connor J. Maxwell
- Department of Biomedical Engineering, University of Arizona, Tucson, AZ, United States
| | - Audrey T. Cohen
- Department of Biomedical Engineering, University of Arizona, Tucson, AZ, United States
| | - Anne M. Wertheimer
- Applied Biosciences GIDP, University of Arizona, Tucson, AZ, United States
- BIO5 Institute, University of Arizona, Tucson, AZ, United States
| | - Minkyu Kim
- Department of Biomedical Engineering, University of Arizona, Tucson, AZ, United States
- BIO5 Institute, University of Arizona, Tucson, AZ, United States
- Department of Materials Science & Engineering, University of Arizona, Tucson, AZ, United States
| |
Collapse
|
19
|
Yusoh NA, Leong SW, Chia SL, Harun SN, Rahman MBA, Vallis KA, Gill MR, Ahmad H. Metallointercalator [Ru(dppz) 2(PIP)] 2+ Renders BRCA Wild-Type Triple-Negative Breast Cancer Cells Hypersensitive to PARP Inhibition. ACS Chem Biol 2020; 15:378-387. [PMID: 31898884 DOI: 10.1021/acschembio.9b00843] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
There is a need to improve and extend the use of clinically approved poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi), including for BRCA wild-type triple-negative breast cancer (TNBC). The demonstration that ruthenium(II) polypyridyl complex (RPC) metallointercalators can rapidly stall DNA replication fork progression provides the rationale for their combination alongside DNA damage response (DDR) inhibitors to achieve synergism in cancer cells. The aim of the present study was to evaluate use of the multi-intercalator [Ru(dppz)2(PIP)]2+ (dppz = dipyrido[3,2-a:2',3'-c]phenazine, PIP = (2-(phenyl)imidazo[4,5-f][1,10]phenanthroline, Ru-PIP) alongside the PARPi olaparib and NU1025. Cell proliferation and clonogenic survival assays indicated a synergistic relationship between Ru-PIP and olaparib in MDA-MB-231 TNBC and MCF7 human breast cancer cells. Strikingly, low dose Ru-PIP renders both cell lines hypersensitive to olaparib, with a >300-fold increase in olaparib potency in TNBC, the largest nongenetic PARPi enhancement effect described to date. A negligible impact on the viability of normal human fibroblasts was observed for any combination tested. Increased levels of DNA double-strand break (DSB) damage and olaparib abrogation of Ru-PIP-activated pChk1 signaling are consistent with PARPi-facilitated collapse of Ru-PIP-associated stalled replication forks. This results in enhanced G2/M cell-cycle arrest, apoptosis, and decreased cell motility for the combination treatment compared to single-agent conditions. This work establishes that an RPC metallointercalator can be combined with PARPi for potent synergy in BRCA-proficient breast cancer cells, including TNBC.
Collapse
Affiliation(s)
- Nur Aininie Yusoh
- Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia
| | - Sze Wei Leong
- Department of Microbiology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia
| | - Suet Lin Chia
- Department of Microbiology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia
- Institute of Bioscience, Universiti Putra Malaysia, 43400 UPM, Serdang, Selangor, Malaysia
| | - Siti Norain Harun
- Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia
| | - Mohd Basyaruddin Abdul Rahman
- Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia
- Integrated Chemical Biophysics Research Centre, Faculty Science, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia
| | - Katherine A. Vallis
- Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, United Kingdom
| | - Martin R. Gill
- Department of Chemistry, College of Science, Swansea University, Swansea, Wales, United Kingdom
| | - Haslina Ahmad
- Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia
- Integrated Chemical Biophysics Research Centre, Faculty Science, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia
| |
Collapse
|
20
|
Patel KD, De Zoysa GH, Kanamala M, Patel K, Pilkington LI, Barker D, Reynisson J, Wu Z, Sarojini V. Novel Cell-Penetrating Peptide Conjugated Proteasome Inhibitors: Anticancer and Antifungal Investigations. J Med Chem 2019; 63:334-348. [DOI: 10.1021/acs.jmedchem.9b01694] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
- Kamal D. Patel
- School of Chemical Sciences and the Centre for Green Chemical Science, University of Auckland, Auckland 1142, New Zealand
| | - Gayan Heruka De Zoysa
- School of Chemical Sciences and the Centre for Green Chemical Science, University of Auckland, Auckland 1142, New Zealand
| | - Manju Kanamala
- School of Pharmacy, University of Auckland, Auckland 1142, New Zealand
| | - Krunal Patel
- School of Chemical Sciences and the Centre for Green Chemical Science, University of Auckland, Auckland 1142, New Zealand
| | - Lisa I. Pilkington
- School of Chemical Sciences and the Centre for Green Chemical Science, University of Auckland, Auckland 1142, New Zealand
| | - David Barker
- School of Chemical Sciences and the Centre for Green Chemical Science, University of Auckland, Auckland 1142, New Zealand
| | - Jóhannes Reynisson
- School of Pharmacy and Bioengineering, Hornbeam Building, Keele University, Staffordshire ST5 5BG, United Kingdom
| | - Zimei Wu
- School of Pharmacy, University of Auckland, Auckland 1142, New Zealand
| | - Vijayalekshmi Sarojini
- School of Chemical Sciences and the Centre for Green Chemical Science, University of Auckland, Auckland 1142, New Zealand
- The MacDiarmid Institute for Advanced Materials and Nanotechnology, Wellington 6140, New Zealand
| |
Collapse
|
21
|
Liu J, Lai H, Xiong Z, Chen B, Chen T. Functionalization and cancer-targeting design of ruthenium complexes for precise cancer therapy. Chem Commun (Camb) 2019; 55:9904-9914. [PMID: 31360938 DOI: 10.1039/c9cc04098f] [Citation(s) in RCA: 84] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The successful clinical application of the three generation platinum anticancer drugs, cisplatin, carboplatin and oxaliplatin, has promoted research interest in metallodrugs; however, the problems of drug resistance and adverse effects have hindered their further application and effects. Thus, scientists are searching for new anticancer metallodrugs with lower toxicity and higher efficacy. The ruthenium complexes have emerged as the most promising alternatives to platinum-based anticancer agents because of their unique multifunctional biochemical properties. In this review, we first focus on the anticancer applications of various ruthenium complexes in different signaling pathways, including the mitochondria-mediated pathway, the DNA damage-mediated pathway, and the death receptor-mediated pathway. We then discuss the functionalization and cancer-targeting designs of different ruthenium complexes in conjunction with other therapies such as photodynamic therapy, photothermal therapy, radiosensitization, targeted therapy and nanotechnology for precise cancer therapy. This review will help in designing and accelerating the research progress regarding new anticancer ruthenium complexes.
Collapse
Affiliation(s)
- Jinggong Liu
- Orthopedics Department, Guangdong Provincial Hospital of Traditional Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 111 Dade Road, Guangzhou 510120, China
| | | | | | | | | |
Collapse
|
22
|
Jackson MR, Bavelaar BM, Waghorn PA, Gill MR, El-Sagheer AH, Brown T, Tarsounas M, Vallis KA. Radiolabeled Oligonucleotides Targeting the RNA Subunit of Telomerase Inhibit Telomerase and Induce DNA Damage in Telomerase-Positive Cancer Cells. Cancer Res 2019; 79:4627-4637. [PMID: 31311806 PMCID: PMC7611324 DOI: 10.1158/0008-5472.can-18-3594] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2018] [Revised: 05/01/2019] [Accepted: 07/12/2019] [Indexed: 12/17/2022]
Abstract
Telomerase is expressed in the majority (>85%) of tumors, but has restricted expression in normal tissues. Long-term telomerase inhibition in malignant cells results in progressive telomere shortening and reduction in cell proliferation. Here we report the synthesis and characterization of radiolabeled oligonucleotides that target the RNA subunit of telomerase, hTR, simultaneously inhibiting enzymatic activity and delivering radiation intracellularly. Oligonucleotides complementary (Match) and noncomplementary (Scramble or Mismatch) to hTR were conjugated to diethylenetriaminepentaacetic dianhydride (DTPA), allowing radiolabeling with the Auger electron-emitting radionuclide indium-111 (111In). Match oligonucleotides inhibited telomerase activity with high potency, which was not observed with Scramble or Mismatch oligonucleotides. DTPA-conjugation and 111In-labeling did not change telomerase inhibition. In telomerase-positive cancer cells, unlabeled Match oligonucleotides had no effect on survival, however, 111In-labeled Match oligonucleotides significantly reduced clonogenic survival and upregulated the DNA damage marker γH2AX. Minimal radiotoxicity and DNA damage was observed in telomerase-negative cells exposed to 111In-Match oligonucleotides. Match oligonucleotides localized in close proximity to nuclear Cajal bodies in telomerase-positive cells. In comparison with Match oligonucleotides, 111In-Scramble or 111In-Mismatch oligonucleotides demonstrated reduced retention and negligible impact on cell survival. This study indicates the therapeutic activity of radiolabeled oligonucleotides that specifically target hTR through potent telomerase inhibition and DNA damage induction in telomerase-expressing cancer cells and paves the way for the development of novel oligonucleotide radiotherapeutics targeting telomerase-positive cancers. SIGNIFICANCE: These findings present a novel radiolabeled oligonucleotide for targeting telomerase-positive cancer cells that exhibits dual activity by simultaneously inhibiting telomerase and promoting radiation-induced genomic DNA damage.
Collapse
Affiliation(s)
- Mark R Jackson
- Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom
| | - Bas M Bavelaar
- Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom
| | - Philip A Waghorn
- Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom
| | - Martin R Gill
- Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom
| | - Afaf H El-Sagheer
- Department of Chemistry, University of Oxford, Oxford, United Kingdom
| | - Tom Brown
- Department of Chemistry, University of Oxford, Oxford, United Kingdom
| | - Madalena Tarsounas
- Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom
| | - Katherine A Vallis
- Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom.
| |
Collapse
|
23
|
Guan S, Pan T, Zhang Y, Zeng Z, Mu L, Zhu D, Chang B, Zheng K, Qian J, Xie Q, Mei W, Tang W, Bai M. Synthesis, DNA-binding, and antitumor activity of polypyridyl-ruthenium(II) complexes [Ru(L)2(DClPIP)] (L = bpy, phen; DClPIP = 2-(2,4-dichlorophenyl)-1H-imidazo[4,5-f][1, 10]phenanthroline). J COORD CHEM 2019. [DOI: 10.1080/00958972.2019.1630614] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- Shouhai Guan
- Department of Vascular Interventional Radiology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - Tao Pan
- Department of Vascular Interventional Radiology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - Yanyang Zhang
- Department of Vascular Interventional Radiology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - Zhaolin Zeng
- Department of Vascular Interventional Radiology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - Luwen Mu
- Department of Vascular Interventional Radiology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - Duo Zhu
- Department of Vascular Interventional Radiology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - Boyang Chang
- Department of Vascular Interventional Radiology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - Kangdi Zheng
- School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China
| | - Jiesheng Qian
- Department of Vascular Interventional Radiology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - Qiang Xie
- Department of Vascular Interventional Radiology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - Wenjie Mei
- School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China
| | - Wenjie Tang
- Department of Vascular Interventional Radiology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - Mingjun Bai
- Department of Vascular Interventional Radiology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| |
Collapse
|
24
|
Beltrán-Leiva MJ, Fuenzalida-Valdivia I, Cantero-López P, Bulhões-Figueira A, Alzate-Morales J, Páez-Hernández D, Arratia-Pérez R. Classical and Quantum Mechanical Calculations of the Stacking Interaction of NdIII Complexes with Regular and Mismatched DNA Sequences. J Phys Chem B 2019; 123:3219-3231. [DOI: 10.1021/acs.jpcb.9b00703] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- María J. Beltrán-Leiva
- Relativistic Molecular Physics Group, Universidad Andres Bello, República 275, Santiago 8370146, Chile
| | - Isabel Fuenzalida-Valdivia
- Facultad de Ciencias Biológicas, Centro de Biotecnología Vegetal, Universidad Andres Bello, Santiago 8370146, Chile
| | - Plinio Cantero-López
- Relativistic Molecular Physics Group, Universidad Andres Bello, República 275, Santiago 8370146, Chile
- Center for Applied Nanosciences (CANS), Facultad de Ciencias Exactas, Universidad Andres Bello, Av. República 275, Santiago, 8370146, Chile
| | - Ana Bulhões-Figueira
- Centro Universitário Estácio de Ribeirão Preto, Rua Abrahão Issa Halach 980, Ribeirãnia, Ribeirão Preto, Sao Paulo 14096-160, Brazil
| | - Jans Alzate-Morales
- Centro de Bioinformática y Simulación Molecular (CBSM), Facultad de Ingeniería, Universidad de Talca, 1 Poniente 1141, Talca, Chile
| | - Dayán Páez-Hernández
- Relativistic Molecular Physics Group, Universidad Andres Bello, República 275, Santiago 8370146, Chile
- Center for Applied Nanosciences (CANS), Facultad de Ciencias Exactas, Universidad Andres Bello, Av. República 275, Santiago, 8370146, Chile
| | - Ramiro Arratia-Pérez
- Relativistic Molecular Physics Group, Universidad Andres Bello, República 275, Santiago 8370146, Chile
- Center for Applied Nanosciences (CANS), Facultad de Ciencias Exactas, Universidad Andres Bello, Av. República 275, Santiago, 8370146, Chile
| |
Collapse
|
25
|
Xu L, Zhang PP, Fang XQ, Liu Y, Wang JQ, Zhou HZ, Chen ST, Chao H. A ruthenium(II) complex containing a p-cresol group induces apoptosis in human cervical carcinoma cells through endoplasmic reticulum stress and reactive oxygen species production. J Inorg Biochem 2019; 191:126-134. [DOI: 10.1016/j.jinorgbio.2018.11.015] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2018] [Revised: 11/21/2018] [Accepted: 11/25/2018] [Indexed: 10/27/2022]
|
26
|
Abstract
Combining metallo-drugs with ionising radiation for synergistic cancer cell killing: chemical design principles, mechanisms of action and emerging applications.
Collapse
Affiliation(s)
- Martin R. Gill
- CRUK/MRC Oxford Institute for Radiation Oncology
- Department of Oncology
- University of Oxford
- Oxford
- UK
| | - Katherine A. Vallis
- CRUK/MRC Oxford Institute for Radiation Oncology
- Department of Oncology
- University of Oxford
- Oxford
- UK
| |
Collapse
|
27
|
Zhou Y, Xu Y, Lu L, Ni J, Nie J, Cao J, Jiao Y, Zhang Q. Luminescent ruthenium(II) polypyridyl complexes acted as radiosensitizer for pancreatic cancer by enhancing radiation-induced DNA damage. Theranostics 2019; 9:6665-6675. [PMID: 31588242 PMCID: PMC6771246 DOI: 10.7150/thno.34015] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2019] [Accepted: 08/05/2019] [Indexed: 12/16/2022] Open
Abstract
Background: Pancreatic cancer is a highly lethal malignancy which ranks 4th most common cause of cancer death in US and 6th in China. Novel drugs are required to improve the survival and prognosis of patients. Methods: Ruthenium(II) complexes with variation number of DIP ligand were synthesized and further adopted as radiosensitizer for pancreatic cancer. The influence of ruthenium(II) complexes on cell behaviors and tumor growth were investigated. The DNA binding affinity of ruthenium(II) complexes and plasmid was measured by using agarose gel electrophoresis. Results: Luminescent ruthenium(II) complex can rapidly enter into cell nuclei and consequently combine with DNA, resulting in the enhanced DNA damage induced by X-ray irradiation. Upon intratumoral injection of ruthenium(II) complex, excellent tumor growth inhibition was accomplished under ionizing radiation of human pancreatic cancer xenograft nude mice. Conclusions: Taken together, our study suggest that the ruthenium(II) polypyridyl complexes can effectively enhance radiation-induced DNA damage, which is likely to benefit the imaging-guided cancer radio-chemotherapy.
Collapse
Affiliation(s)
- Yuyang Zhou
- School of Chemistry, Biology and Materials Engineering, Jiangsu Key Laboratory of Environmental Functional Materials, Suzhou University of Science and Technology, Suzhou, Jiangsu, 215009, P. R. China
- ✉ Corresponding authors: Prof. Yuyang Zhou, E-mail: . Prof. Yang Jiao, Tel: +86 0512-65883941, E-mail: . Prof. Qi Zhang, Tel: +86 0512-65883941,
| | - Ying Xu
- School of Radiation Medicine and Protection, State Key Laboratory of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou, Jiangsu 215123, P. R. China
| | - Lunjie Lu
- Department of Radiation Physics, Qingdao Central Hospital, Qingdao, Shandong, 266000, P. R. China
| | - Jingyang Ni
- School of Chemistry, Biology and Materials Engineering, Jiangsu Key Laboratory of Environmental Functional Materials, Suzhou University of Science and Technology, Suzhou, Jiangsu, 215009, P. R. China
| | - Jihua Nie
- School of Radiation Medicine and Protection, State Key Laboratory of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou, Jiangsu 215123, P. R. China
| | - Jianping Cao
- School of Radiation Medicine and Protection, State Key Laboratory of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou, Jiangsu 215123, P. R. China
| | - Yang Jiao
- School of Radiation Medicine and Protection, State Key Laboratory of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou, Jiangsu 215123, P. R. China
- ✉ Corresponding authors: Prof. Yuyang Zhou, E-mail: . Prof. Yang Jiao, Tel: +86 0512-65883941, E-mail: . Prof. Qi Zhang, Tel: +86 0512-65883941,
| | - Qi Zhang
- School of Radiation Medicine and Protection, State Key Laboratory of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou, Jiangsu 215123, P. R. China
- ✉ Corresponding authors: Prof. Yuyang Zhou, E-mail: . Prof. Yang Jiao, Tel: +86 0512-65883941, E-mail: . Prof. Qi Zhang, Tel: +86 0512-65883941,
| |
Collapse
|
28
|
Sun N, Zhao C, Cheng R, Liu Z, Li X, Lu A, Tian Z, Yang Z. Cargo-Free Nanomedicine with pH Sensitivity for Codelivery of DOX Conjugated Prodrug with SN38 To Synergistically Eradicate Breast Cancer Stem Cells. Mol Pharm 2018; 15:3343-3355. [PMID: 29923726 DOI: 10.1021/acs.molpharmaceut.8b00367] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
As a result of their ability to transform into bulk cancer cells and their resistance to radiotherapy and chemotherapy, cancer stem cells (CSCs) are currently considered as a major obstacle for cancer treatment. Application of multiple drugs using nanocarriers is a promising approach to simultaneously eliminate noncancer stem cells (non-CSCs) and CSCs. Herein, to employ the advantages of nanomedicine while avoiding new excipients, pH-responsive prodrug (PEG-CH═N-DOX) was employed as the surfactant to fabricate cargo-free nanomedicine for codelivery of DOX conjugated prodrug with SN38 to synergistically eradicate breast cancer stem cells (bCSCs) and non-bCSCs. Through the intermolecular interaction between DOX and SN38, PEG-CH═N-DOX and SN38 were assembled together to form a stable nanomedicine. This nanomedicine not only dramatically enhanced drug accumulation efficiency at the tumor site but also effectively eliminated bCSCs and non-bCSCs, which resulted in achieving a superior in vivo tumor inhibition activity. Additionally, the biosafety of this nanomedicine was systematically studied through immunohistochemistry, blood biochemistry assay, blood routine examination, and metabolomics. The results revealed that this nanomedicine significantly reduced the adverse effects of DOX and SN38. Therefore, this simple yet efficient nanomedicine provided a promising strategy for future clinical applications.
Collapse
|
29
|
Gill MR, Menon JU, Jarman PJ, Owen J, Skaripa-Koukelli I, Able S, Thomas JA, Carlisle R, Vallis KA. 111In-labelled polymeric nanoparticles incorporating a ruthenium-based radiosensitizer for EGFR-targeted combination therapy in oesophageal cancer cells. NANOSCALE 2018; 10:10596-10608. [PMID: 29808844 PMCID: PMC5994990 DOI: 10.1039/c7nr09606b] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/24/2017] [Accepted: 04/17/2018] [Indexed: 05/14/2023]
Abstract
Radiolabelled, drug-loaded nanoparticles may combine the theranostic properties of radionuclides, the controlled release of chemotherapy and cancer cell targeting. Here, we report the preparation of poly(lactic-co-glycolic acid) (PLGA) nanoparticles surface conjugated to DTPA-hEGF (DTPA = diethylenetriaminepentaacetic acid, hEGF = human epidermal growth factor) and encapsulating the ruthenium-based DNA replication inhibitor and radiosensitizer Ru(phen)2(tpphz)2+ (phen = 1,10-phenanthroline, tpphz = tetrapyridophenazine) Ru1. The functionalized PLGA surface incorporates the metal ion chelator DTPA for radiolabelling and the targeting ligand for EGF receptor (EGFR). Nanoparticles radiolabelled with 111In are taken up preferentially by EGFR-overexpressing oesophageal cancer cells, where they exhibit radiotoxicity through the generation of cellular DNA damage. Moreover, nanoparticle co-delivery of Ru1 alongside 111In results in decreased cell survival compared to single-agent formulations; an effect that occurs through DNA damage enhancement and an additive relationship between 111In and Ru1. Substantially decreased uptake and radiotoxicity of nanoparticles towards normal human fibroblasts and oesophageal cancer cells with normal EGFR levels is observed. This work demonstrates nanoparticle co-delivery of a therapeutic radionuclide plus a ruthenium-based radiosensitizer can achieve combinational and targeted therapeutic effects in cancer cells that overexpress EGFR.
Collapse
Affiliation(s)
- Martin R. Gill
- CRUK/MRC Oxford Institute for Radiation Oncology
, Department of Oncology
, University of Oxford
,
Oxford
, UK
.
| | - Jyothi U. Menon
- CRUK/MRC Oxford Institute for Radiation Oncology
, Department of Oncology
, University of Oxford
,
Oxford
, UK
.
- Institute of Biomedical Engineering
, Department of Engineering Science
, University of Oxford
, Old Road Campus Research Building
,
Oxford OX3 7DQ
, UK
| | - Paul J. Jarman
- Department of Chemistry
, University of Sheffield
,
Sheffield
, UK
| | - Joshua Owen
- Institute of Biomedical Engineering
, Department of Engineering Science
, University of Oxford
, Old Road Campus Research Building
,
Oxford OX3 7DQ
, UK
| | - Irini Skaripa-Koukelli
- CRUK/MRC Oxford Institute for Radiation Oncology
, Department of Oncology
, University of Oxford
,
Oxford
, UK
.
- Institute of Biomedical Engineering
, Department of Engineering Science
, University of Oxford
, Old Road Campus Research Building
,
Oxford OX3 7DQ
, UK
| | - Sarah Able
- CRUK/MRC Oxford Institute for Radiation Oncology
, Department of Oncology
, University of Oxford
,
Oxford
, UK
.
| | - Jim A. Thomas
- Department of Chemistry
, University of Sheffield
,
Sheffield
, UK
| | - Robert Carlisle
- Institute of Biomedical Engineering
, Department of Engineering Science
, University of Oxford
, Old Road Campus Research Building
,
Oxford OX3 7DQ
, UK
| | - Katherine A. Vallis
- CRUK/MRC Oxford Institute for Radiation Oncology
, Department of Oncology
, University of Oxford
,
Oxford
, UK
.
| |
Collapse
|
30
|
Poynton FE, Bright SA, Blasco S, Williams DC, Kelly JM, Gunnlaugsson T. The development of ruthenium(ii) polypyridyl complexes and conjugates for in vitro cellular and in vivo applications. Chem Soc Rev 2018; 46:7706-7756. [PMID: 29177281 DOI: 10.1039/c7cs00680b] [Citation(s) in RCA: 284] [Impact Index Per Article: 47.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Ruthenium(ii) [Ru(ii)] polypyridyl complexes have been the focus of intense investigations since work began exploring their supramolecular interactions with DNA. In recent years, there have been considerable efforts to translate this solution-based research into a biological environment with the intention of developing new classes of probes, luminescent imaging agents, therapeutics and theranostics. In only 10 years the field has expanded with diverse applications for these complexes as imaging agents and promising candidates for therapeutics. In light of these efforts this review exclusively focuses on the developments of these complexes in biological systems, both in cells and in vivo, and hopes to communicate to readers the diversity of applications within which these complexes have found use, as well as new insights gained along the way and challenges that researchers in this field still face.
Collapse
Affiliation(s)
- Fergus E Poynton
- School of Chemistry and Trinity Biomedical Sciences Institute (TBSI), Trinity College Dublin, The University of Dublin, Dublin 2, Ireland.
| | | | | | | | | | | |
Collapse
|
31
|
van Rixel VHS, Moolenaar GF, Siegler MA, Messori L, Bonnet S. Controlling with light the interaction between trans-tetrapyridyl ruthenium complexes and an oligonucleotide. Dalton Trans 2018; 47:507-516. [PMID: 29230469 DOI: 10.1039/c7dt03613b] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Three new trans-ruthenium(ii) complexes coordinated to tetrapyridyl ligands, namely [Ru(bapbpy)(dmso)Cl]Cl ([2]Cl), [Ru(bapbpy)(Hmte)2](PF6)2 ([3](PF6)2), and [Ru(biqbpy)(Hmte)2](PF6)2 ([4](PF6)2), were prepared as analogues of [Ru(biqbpy)(dmso)Cl]Cl ([1]Cl), a recently described photoactivated chemotherapy agent. The new complexes were characterized, and their crystal structures showed the distorted coordination octahedron typical of this family of complexes. Their photoreactivity in solution was analyzed by spectrophotometry and mass spectrometry, which showed that the sulfur ligand was substituted upon blue light irradiation. The binding of the ruthenium complexes to a reference single-stranded oligonucleotide (s(5'CTACGGTTTCAC3')) was explored both in the dark and under light irradiation by gel electrophoresis and high-resolution mass spectrometry. While adduct formation in the dark was negligible for the four complexes, light irradiation led to the formation of adducts with one or two ruthenium centers per oligonucleotide. The absence of interactions in the dark and the presence of complex-oligonucleotide adducts demonstrate that visible light controls the interaction of these ruthenium complexes with nucleic acids.
Collapse
Affiliation(s)
- Vincent H S van Rixel
- Leiden University, Leiden Institute of Chemistry, Gorlaeus Laboratories, P.O. Box 9502, 2300 RA Leiden, The Netherlands.
| | | | | | | | | |
Collapse
|
32
|
Gill MR, Jarman PJ, Halder S, Walker MG, Saeed HK, Thomas JA, Smythe C, Ramadan K, Vallis KA. A three-in-one-bullet for oesophageal cancer: replication fork collapse, spindle attachment failure and enhanced radiosensitivity generated by a ruthenium(ii) metallo-intercalator. Chem Sci 2018; 9:841-849. [PMID: 29629151 PMCID: PMC5870190 DOI: 10.1039/c7sc03712k] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2017] [Accepted: 11/16/2017] [Indexed: 12/23/2022] Open
Abstract
Substitutionally inert ruthenium(ii) polypyridyl complexes have been developed as DNA intercalating agents yet cellular DNA damage responses to this binding modality are largely unexplored. Here, we show the nuclear-targeting complex [Ru(phen)2(tpphz)]2+ (phen = 1,10-phenanthroline, tpphz = tetrapyridophenazine) generates rapid and pronounced stalling of replication fork progression in p53-deficient human oesophageal cancer cells. In response, replication stress and double-strand break (DSB) DNA damage response (DDR) pathways are activated and cell proliferation is inhibited by growth arrest. Moreover, mitotic progression is compromised by [Ru(phen)2(tpphz)]2+, where the generation of metaphase chromosome spindle attachment failure results in spindle assembly checkpoint (SAC) activation. This dual mechanism of action results in preferential growth inhibition of rapidly-proliferating oesophageal cancer cells with elevated mitotic indices. In addition to these single-agent effects, [Ru(phen)2(tpphz)]2+ functions as a radiosensitizer with efficiency comparable to cisplatin, which occurs through a synergistic enhancement of DNA damage. These results establish that DNA replication is the target for [Ru(phen)2(tpphz)]2+ and provide the first experimental evidence that ruthenium-based intercalation targets multiple genome integrity pathways in cancer cells, thereby achieving enhanced selectivity compared to existing DNA-damaging agents such as cisplatin.
Collapse
Affiliation(s)
- Martin R Gill
- CRUK/MRC Oxford Institute for Radiation Oncology , Department of Oncology , University of Oxford , Oxford , UK . ;
| | - Paul J Jarman
- Department of Chemistry , University of Sheffield , Sheffield , UK
- Department of Biomedical Science , University of Sheffield , Sheffield , UK
| | - Swagata Halder
- CRUK/MRC Oxford Institute for Radiation Oncology , Department of Oncology , University of Oxford , Oxford , UK . ;
| | - Michael G Walker
- Department of Chemistry , University of Sheffield , Sheffield , UK
| | - Hiwa K Saeed
- Department of Chemistry , University of Sheffield , Sheffield , UK
| | - Jim A Thomas
- Department of Chemistry , University of Sheffield , Sheffield , UK
| | - Carl Smythe
- Department of Biomedical Science , University of Sheffield , Sheffield , UK
| | - Kristijan Ramadan
- CRUK/MRC Oxford Institute for Radiation Oncology , Department of Oncology , University of Oxford , Oxford , UK . ;
| | - Katherine A Vallis
- CRUK/MRC Oxford Institute for Radiation Oncology , Department of Oncology , University of Oxford , Oxford , UK . ;
| |
Collapse
|
33
|
Zeng L, Gupta P, Chen Y, Wang E, Ji L, Chao H, Chen ZS. The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials. Chem Soc Rev 2017; 46:5771-5804. [PMID: 28654103 PMCID: PMC5624840 DOI: 10.1039/c7cs00195a] [Citation(s) in RCA: 710] [Impact Index Per Article: 101.4] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Cancer is rapidly becoming the top killer in the world. Most of the FDA approved anticancer drugs are organic molecules, while metallodrugs are very scarce. The advent of the first metal based therapeutic agent, cisplatin, launched a new era in the application of transition metal complexes for therapeutic design. Due to their unique and versatile biochemical properties, ruthenium-based compounds have emerged as promising anti-cancer agents that serve as alternatives to cisplatin and its derivertives. Ruthenium(iii) complexes have successfully been used in clinical research and their mechanisms of anticancer action have been reported in large volumes over the past few decades. Ruthenium(ii) complexes have also attracted significant attention as anticancer candidates; however, only a few of them have been reported comprehensively. In this review, we discuss the development of ruthenium(ii) complexes as anticancer candidates and biocatalysts, including arene ruthenium complexes, polypyridyl ruthenium complexes, and ruthenium nanomaterial complexes. This review focuses on the likely mechanisms of action of ruthenium(ii)-based anticancer drugs and the relationship between their chemical structures and biological properties. This review also highlights the catalytic activity and the photoinduced activation of ruthenium(ii) complexes, their targeted delivery, and their activity in nanomaterial systems.
Collapse
Affiliation(s)
- Leli Zeng
- College of Pharmacy and Health Sciences, St. John's University, New York, NY 11439, USA.
| | | | | | | | | | | | | |
Collapse
|
34
|
Salehi F, Behboudi H, Kavoosi G, Ardestani SK. Monitoring ZEO apoptotic potential in 2D and 3D cell cultures and associated spectroscopic evidence on mode of interaction with DNA. Sci Rep 2017; 7:2553. [PMID: 28566685 PMCID: PMC5451462 DOI: 10.1038/s41598-017-02633-z] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2016] [Accepted: 04/07/2017] [Indexed: 12/21/2022] Open
Abstract
Recognizing new anticancer compounds to improve Breast cancer treatment seems crucial. Essential oil of Zataria Multiflora (ZEO) is a secondary metabolite with some biological properties, yet underlying cellular and molecular anticancer properties of ZEO is unclear. GC/MS analysis revealed that carvacrol is the major ingredient of the essential oil. ZEO increasingly suppressed viability in MDA-MB-231, MCF-7 and T47D Breast cancer cells while nontoxic to L929 normal cells in monolayer cell cultures (2D), whereas MDA-MB-231 multicellular spheroids (3D) were more resistant to inhibition. ZEO significantly induced cell apoptosis confirmed by fluorescent staining, flow cytometry analysis and DNA fragmentation in MDA-MB-231 2D and 3D cell cultures. ZEO increased ROS generation and subsequent loss of ΔΨm, caspase 3 activation and DNA damage which consequently caused G1 and G2/M cell cycle arrest in a dose- and time-dependent manner in 2D. S phase arrest occurred in cell spheroids therefore ZEO possible DNA interaction with gDNA was investigated and revealed ZEO binds DNA via intercalation. Altogether, these data corroborate anticancer properties of ZEO and suggest that cell culture format (2D monolayer vs. 3D spheroid) plays a critical role in drug response and provides new insights into the mechanisms underlying ZEO cytotoxicity effect on Breast cancer cells.
Collapse
Affiliation(s)
- Fahimeh Salehi
- Institute of Biochemistry and Biophysics, Department of Biochemistry, University of Tehran, Tehran, Iran
| | - Hossein Behboudi
- Institute of Biochemistry and Biophysics, Department of Biochemistry, University of Tehran, Tehran, Iran
| | | | - Sussan K Ardestani
- Institute of Biochemistry and Biophysics, Department of Biochemistry, University of Tehran, Tehran, Iran.
| |
Collapse
|
35
|
Thangavel P, Viswanath B, Kim S. Recent developments in the nanostructured materials functionalized with ruthenium complexes for targeted drug delivery to tumors. Int J Nanomedicine 2017; 12:2749-2758. [PMID: 28435255 PMCID: PMC5388259 DOI: 10.2147/ijn.s131304] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
In recent years, the field of metal-based drugs has been dominated by other existing precious metal drugs, and many researchers have focused their attention on the synthesis of various ruthenium (Ru) complexes due to their potential medical and pharmaceutical applications. The beneficial properties of Ru, which make it a highly promising therapeutic agent, include its variable oxidation states, low toxicity, high selectivity for diseased cells, ligand exchange properties, and the ability to mimic iron binding to biomolecules. In addition, Ru complexes have favorable adsorption properties, along with excellent photochemical and photophysical properties, which make them promising tools for photodynamic therapy. At present, nanostructured materials functionalized with Ru complexes have become an efficient way to administer Ru-based anticancer drugs for cancer treatment. In this review, the recent developments in the nanostructured materials functionalized with Ru complexes for targeted drug delivery to tumors are discussed. In addition, information on "traditional" (ie, non-nanostructured) Ru-based cancer therapies is included in a precise manner.
Collapse
Affiliation(s)
- Prakash Thangavel
- Department of Bionanotechnology, Gachon University, Bokjeong-Dong, Sujeong-Gu, Seongnam-Si, Gyeonggi-Do
| | - Buddolla Viswanath
- Department of Bionanotechnology, Gachon University, Bokjeong-Dong, Sujeong-Gu, Seongnam-Si, Gyeonggi-Do
| | - Sanghyo Kim
- Department of Bionanotechnology, Gachon University, Bokjeong-Dong, Sujeong-Gu, Seongnam-Si, Gyeonggi-Do
- Graduate Gachon Medical Research Institute, Gil Medical Center, Incheon, Republic of Korea
| |
Collapse
|
36
|
Yin Y, Shen Q, Zhang P, Tao R, Chang W, Li R, Xie G, Liu W, Zhang L, Kapoor P, Song S, Ajani J, Mills GB, Chen J, Tao K, Peng G. Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. Am J Cancer Res 2017; 7:473-483. [PMID: 28401005 PMCID: PMC5385637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2017] [Accepted: 02/10/2017] [Indexed: 06/07/2023] Open
Abstract
Globally, gastric cancer is the second leading cause of cancer deaths because of the lack of effective treatments for patients with advanced tumors when curative surgery is not possible. Thus, there is an urgent need to identify molecular targets in gastric cancer that can be used for developing novel therapies and prolonging patient survival. Checkpoint kinase 1 (Chk1) is a crucial regulator of cell cycle transition in DNA damage response (DDR). In our study, we report that Chk1 plays an important role in promoting gastric cancer cell survival and growth, which serves as an effective therapeutic target in gastric cancer. First, Chk1 ablation by small interfering RNA could significantly inhibit cell proliferation and sensitize the effects of ionizing radiation (IR) treatment in both p53 wild type gastric cancer cell line AGS, and p53 mutant cell line MKN1. Secondly, we tested the anticancer effects of Chk1 chemical inhibitor LY2606368, which is a novel Chk1/2 targeted drug undergoing clinical trials in many malignant diseases. We found that LY2606368 can induce DNA damage, and remarkably suppress cancer proliferation and induce apoptosis in AGS and MKN1 cells. Moreover, we identified that LY2606368 can significantly inhibit homologous recombination (HR) mediated DNA repair and thus showed marked synergistic anticancer effect in combination with poly (ADP-ribose) polymerase 1 (PARP1) inhibitor BMN673 in both in vitro studies and in vivo experiments using a gastric cancer PDx model. The synergy between LY2606368 and PARP1 was likely caused by impaired the G2M checkpoint due to LY2606368 treatment, which forced mitotic entry and cell death in the presence of BMN673. In conclusion, we propose that Chk1 is a valued target for gastric cancer treatment, especially Chk1 inhibitor combined with PARP inhibitor may be a more effective therapeutic strategy in gastric cancer.
Collapse
Affiliation(s)
- Yuping Yin
- Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, Hubei, China
- Department of Clinical Cancer Prevention, The University of Texas, MD Anderson Cancer CenterHouston, TX, USA
| | - Qian Shen
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, Hubei, China
| | - Peng Zhang
- Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, Hubei, China
| | - Ruikang Tao
- Center for Biomolecular Science and Engineering, University of California Santa CruzSanta Cruz, CA, USA
| | - Weilong Chang
- Department of Gastrointestinal Surgery, The First Affiliated Hospital of ZhengzhouHenan, China
| | - Ruidong Li
- Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, Hubei, China
| | - Gengchen Xie
- Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, Hubei, China
| | - Weizhen Liu
- Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, Hubei, China
| | - Lihong Zhang
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, Hubei, China
| | - Prabodh Kapoor
- Department of Cellular and Molecular Biology, The University of Texas Health Science Center at TylerTyler, TX, USA
| | - Shumei Song
- Department of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer CenterHouston, TX, USA
| | - Jaffer Ajani
- Department of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer CenterHouston, TX, USA
| | - Gordon B Mills
- Department of Systems Biology, The University of Texas, MD Anderson Cancer CenterHouston, TX, USA
| | - Jianying Chen
- Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, Hubei, China
| | - Kaixiong Tao
- Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, Hubei, China
| | - Guang Peng
- Department of Clinical Cancer Prevention, The University of Texas, MD Anderson Cancer CenterHouston, TX, USA
| |
Collapse
|
37
|
Karaca Ö, Meier-Menches SM, Casini A, Kühn FE. On the binding modes of metal NHC complexes with DNA secondary structures: implications for therapy and imaging. Chem Commun (Camb) 2017; 53:8249-8260. [DOI: 10.1039/c7cc03074f] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
This perspective review aims at providing an overview of the most representative examples of bioactive metal NHC complexes reacting with nucleic acidsviadifferent binding modes.
Collapse
Affiliation(s)
- Özden Karaca
- Molecular Catalysis
- Department of Chemistry
- Catalysis Research Center
- Technische Universität München
- 85747 Garching bei München
| | | | - Angela Casini
- School of Chemistry
- Cardiff University
- CF103AT Cardiff
- UK
- Institute of Advanced Studies
| | - Fritz E. Kühn
- Molecular Catalysis
- Department of Chemistry
- Catalysis Research Center
- Technische Universität München
- 85747 Garching bei München
| |
Collapse
|
38
|
Ramu V, Aute S, Taye N, Guha R, Walker MG, Mogare D, Parulekar A, Thomas JA, Chattopadhyay S, Das A. Photo-induced cytotoxicity and anti-metastatic activity of ruthenium(ii)–polypyridyl complexes functionalized with tyrosine or tryptophan. Dalton Trans 2017; 46:6634-6644. [DOI: 10.1039/c7dt00670e] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
The synergestic effect of oxygen, light, and photosensitizer has found application in photodyanmic therapy (PDT).
Collapse
Affiliation(s)
- Vadde Ramu
- Organic Chemistry Division
- CSIR-National Chemical Laboratory
- Pune
- India
| | - Sunil Aute
- Organic Chemistry Division
- CSIR-National Chemical Laboratory
- Pune
- India
| | - Nandaraj Taye
- Chromatin and Disease Biology Laboratory
- National Centre for Cell Science
- Pune
- India
| | - Rweetuparna Guha
- Organic Chemistry Division
- CSIR-National Chemical Laboratory
- Pune
- India
| | | | - Devaraj Mogare
- Chromatin and Disease Biology Laboratory
- National Centre for Cell Science
- Pune
- India
| | - Apoorva Parulekar
- Chromatin and Disease Biology Laboratory
- National Centre for Cell Science
- Pune
- India
| | - Jim A. Thomas
- Department of Chemistry
- University of Sheffield
- Sheffield
- UK
| | - Samit Chattopadhyay
- Chromatin and Disease Biology Laboratory
- National Centre for Cell Science
- Pune
- India
- Indian Institute of Chemical Biology
| | - Amitava Das
- Organic Chemistry Division
- CSIR-National Chemical Laboratory
- Pune
- India
- CSIR-Central Salt and marine Chemicals Research Institute
| |
Collapse
|
39
|
Salehi F, Behboudi H, Kavoosi G, Ardestani SK. Chitosan promotes ROS-mediated apoptosis and S phase cell cycle arrest in triple-negative breast cancer cells: evidence for intercalative interaction with genomic DNA. RSC Adv 2017. [DOI: 10.1039/c7ra06793c] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
Chitosan (CS) is a semi-synthetic bio-based polysaccharide with promising biological and antitumor properties.
Collapse
Affiliation(s)
- Fahimeh Salehi
- Institute of Biochemistry and Biophysics
- Department of Biochemistry
- University of Tehran
- Tehran
- Iran
| | - Hossein Behboudi
- Institute of Biochemistry and Biophysics
- Department of Biochemistry
- University of Tehran
- Tehran
- Iran
| | | | - Sussan K. Ardestani
- Institute of Biochemistry and Biophysics
- Department of Biochemistry
- University of Tehran
- Tehran
- Iran
| |
Collapse
|
40
|
Tsovaltzi E, Malamidou-Xenikaki E, Dalezis P, Hatzidimitriou A, Lazarides T, Trafalis D, Sarli V. Synthesis and analysis of the anticancer activity of Ru( ii) complexes incorporating 2-hydroxymethylidene-indene-1,3-dione ligands. NEW J CHEM 2017. [DOI: 10.1039/c7nj02162c] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Piano-stool Ru(ii) complexes incorporating 2-hydroxymethylidene-indene-1,3-dione ligands exhibit promising anticancer activity against four human ovarian cancer cell lines.
Collapse
Affiliation(s)
- E. Tsovaltzi
- Department of Chemistry
- Aristotle University of Thessaloniki
- University Campus
- Thessaloniki
- Greece
| | - E. Malamidou-Xenikaki
- Department of Chemistry
- Aristotle University of Thessaloniki
- University Campus
- Thessaloniki
- Greece
| | - P. Dalezis
- Laboratory of Pharmacology
- Medical School National and Kapodistrian University of Athens
- Athens
- Greece
| | - A. Hatzidimitriou
- Department of Chemistry
- Aristotle University of Thessaloniki
- University Campus
- Thessaloniki
- Greece
| | - T. Lazarides
- Department of Chemistry
- Aristotle University of Thessaloniki
- University Campus
- Thessaloniki
- Greece
| | - D. Trafalis
- Laboratory of Pharmacology
- Medical School National and Kapodistrian University of Athens
- Athens
- Greece
| | - V. Sarli
- Department of Chemistry
- Aristotle University of Thessaloniki
- University Campus
- Thessaloniki
- Greece
| |
Collapse
|